Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049381 | 0.84 | ALDH1A1 (0.71) | SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL5487080 | 0.83 | SIGMAR1 (0.66) | SIGMAR1DRD2DRD4KDM4EALDH1A1 | |
| SCHEMBL22813625 | 0.83 | HRH3 (0.83) | SIGMAR1HRH3DRD2DRD4HTR2B | |
| SCHEMBL3449498 | 0.82 | SIGMAR1 (0.50) | SIGMAR1DRD2KDM4EALDH1A1 | |
| SCHEMBL18672550 | 0.82 | SIGMAR1 (1.00) | SIGMAR1HRH3HTR1A | |
| Hydrochloric Acid SCHEMBL27726278 | 0.81 | SIGMAR1 (0.97) | SIGMAR1HRH3HTR1A | |
| Hydrochloric Acid SCHEMBL10352286 | 0.80 | HRH3 (0.78) | SIGMAR1HRH3DRD2DRD4HTR2B | |
| SCHEMBL3964783 | 0.80 | DRD3 (0.57) | SIGMAR1DRD2DRD4DRD3KDM4E | |
| SCHEMBL11786563 | 0.79 | SIGMAR1 (0.71) | SIGMAR1HRH3DRD2DRD4HTR2B | |
| SCHEMBL12961311 | 0.79 | SIGMAR1 (0.53) | SIGMAR1DRD2DRD3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7538252-B2 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538252-B2 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2008030892-A2 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | TUBB, TUBA1C, TUBB1 | SIGMAR1 3432/4885HRH3 3941/4885DRD2 3631/4885 |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | TUBB, TUBA1C, TUBB1 | SIGMAR1 3432/4885HRH3 3941/4885DRD2 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.